<DOC>
	<DOCNO>NCT00676338</DOCNO>
	<brief_summary>This study compare effect 2.0 mg exenatide weekly injection monotherapy 3 active comparators ( metformin , dipeptidyl peptidase-4 inhibitor , thiazolidinedione ) drug naive patient type 2 diabetes treat diet exercise .</brief_summary>
	<brief_title>Safety Efficacy Exenatide Once Weekly Injection Versus Metformin , Dipeptidyl Peptidase-4 Inhibitor , Thiazolidinedione Monotherapy Drug-Naive Patients With Type 2 Diabetes ( DURATION-4 )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<mesh_term>2,4-thiazolidinedione</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<mesh_term>Dipeptidyl-Peptidase IV Inhibitors</mesh_term>
	<criteria>type 2 diabetes treat diet exercise alone . least 18 year age . HbA1c 7.1 % 11.0 % , inclusive . Body mass index ( BMI ) 23 kg/m2 45 kg/m2 , inclusive . Have history stable body weight ( vary &gt; 5 % least 3 month prior screen ) . Have history cardiac disease presence active cardiac disease within year prior inclusion study include myocardial infarction , clinically significant arrhythmia , unstable angina , moderate severe congestive heart failure , coronary artery bypass surgery , angioplasty Have history renal transplantation currently receive renal dialysis Have active untreated malignancy , remission clinically significant malignancy ( basal cell squamous cell skin cancer , situ carcinoma cervix , situ prostate cancer ) less 5 year . Have history severe GI disorder ( e.g. , gastroparesis ) Have history acute chronic pancreatitis . Have active proliferative retinopathy . Have treat drug promote weight loss ( e.g. , Xenical速 [ orlistat ] , Meridia速 [ sibutramine ] , Acomplia速 [ rimonabant ] , Acutrim速 [ phenylpropanolamine ] , similar overthecounter medication ) within 3 month screen . Have treat antidiabetic agent 7 day within 3 month prior screen . Have organ transplant . Have previously complete discontinue study drug study , withdrawn study study investigate exenatide weekly . Have receive treatment within last 30 day drug receive regulatory approval indication time study entry . Are currently enrol clinical study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Amylin</keyword>
	<keyword>Lilly</keyword>
	<keyword>exenatide weekly</keyword>
	<keyword>Byetta</keyword>
	<keyword>Januvia</keyword>
	<keyword>sitagliptin</keyword>
	<keyword>thiazolidinedione</keyword>
</DOC>